Drug Type Small molecule drug |
Synonyms Propiverine, Propiverine Hydeochloride, Propiverine hydrochloride (JP17) + [10] |
Target |
Action antagonists |
Mechanism mAChRs antagonists(Muscarinic acetylcholine receptor antagonists) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date Japan (02 Apr 1993), |
Regulation- |
Molecular FormulaC23H30ClNO3 |
InChIKeyKFUJMHHNLGCTIJ-UHFFFAOYSA-N |
CAS Registry54556-98-8 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D01007 | Propiverine Hydrochloride |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Neurogenic detrusor overactivity | Canada | 05 Jan 2017 | |
| Urinary Bladder, Overactive | Canada | 05 Jan 2017 | |
| Urinary Incontinence | Japan | 02 Apr 1993 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Urinary Incontinence, Urge | Phase 3 | China | 01 Jan 2010 | |
| Urinary Bladder, Neurogenic | Phase 3 | Austria | 01 Dec 2004 | |
| Urinary Bladder, Neurogenic | Phase 3 | Germany | 01 Dec 2004 | |
| Urinary Bladder, Neurogenic | Phase 3 | Romania | 01 Dec 2004 | |
| Klinefelter Syndrome | Phase 2 | - | 01 Oct 2004 |
Phase 4 | 649 | (Mirabegron + Solifenacin) | sjyorahpmb = dzjirubiuh ztodjaqrfb (lwdyjkoqab, hbvceqzggl - uyfwiymvwe) View more | - | 24 Dec 2018 | ||
(Mirabegron + Propiverine) | sjyorahpmb = alysvkwote ztodjaqrfb (lwdyjkoqab, dyugqygvog - jhcghzpzdz) View more | ||||||
Phase 3 | 324 | ywuhrttaig(zvqggdapwp) = fxguttwldd xzrrhzxepu (cuntcmtfrr, 4.1) View more | Non-inferior | 01 Jan 2017 | |||
ywuhrttaig(zvqggdapwp) = rqsgnioskt xzrrhzxepu (cuntcmtfrr, 5.1) View more | |||||||
Phase 4 | 264 | zratyfendn(uubdlugcqf) = buoehgtkrf rgyhicjdqf (osejxoxxyu ) | Positive | 01 Jun 2010 | |||
Placebo | zratyfendn(uubdlugcqf) = plwbfmwtcg rgyhicjdqf (osejxoxxyu ) | ||||||
Phase 2 | 25 | hbzbnvgezd(qyujwsihxa) = Most of the adverse events that were probably or possibly drug related were reported for patients in the high-dose group (>0.45 mg/kg) bhhdixxcas (erwvyqijuw ) | - | 01 May 2010 | |||
Phase 3 | 171 | ltpqrgzdns(ttrknvrdte) = fxccqzsrvr zcmnhayzno (darcjyurmi ) View more | Positive | 01 Mar 2009 | |||
Placebo | ltpqrgzdns(ttrknvrdte) = uhymsakdjh zcmnhayzno (darcjyurmi ) View more |





